Semaglutide Injections

Semaglutide is a revolutionary GLP-1 receptor agonist that was originally developed for patients with Type 2 diabetes, but when providers and pharmaceutical developers noticed how much weight their patients were losing, they began to study semaglutide exclusively for weight loss. A series of clinical trials known as the STEP clinical trials demonstrated that almost 90% of patients lost 5% or more of their body weight. There is no other weight loss drug on the market that compares. In June of 2022, the FDA approved semaglutide for weight loss. 

Semaglutide acts like GLP-1 (a gut hormone) to:         

Increase insulin production       

Decrease glucagon synthesis       

Delay gastric emptying           

Suppress hunger

It signals your brain that you are full so you can loose weight without feeling like you are depriving yourself. 

Commonly reported GI side effects - nausea, vomiting, diarrhea, constipation, abdominal pain, site reactions, fatigue and headaches